Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Net Income towards Common Stockholders (2019 - 2025)

Benitec Biopharma has reported Net Income towards Common Stockholders over the past 7 years, most recently at -$11.8 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$11.8 million for Q4 2025, down 60.89% from a year ago — trailing twelve months through Dec 2025 was -$44.1 million (down 105.97% YoY), and the annual figure for FY2025 was -$37.9 million, down 69.5%.
  • Net Income towards Common Stockholders reached -$11.8 million in Q4 2025 per BNTC's latest filing, down from -$9.0 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$3.5 million in Q1 2022 and bottomed at -$14.5 million in Q1 2025.
  • Median Net Income towards Common Stockholders over the past 5 years was -$4.8 million (2021), compared with a mean of -$6.2 million.
  • The largest annual shift saw Net Income towards Common Stockholders grew 23.03% in 2024 before it crashed 238.89% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at -$4.8 million in 2021, then decreased by 15.95% to -$5.6 million in 2022, then decreased by 20.98% to -$6.8 million in 2023, then decreased by 8.22% to -$7.4 million in 2024, then plummeted by 60.89% to -$11.8 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for BNTC at -$11.8 million in Q4 2025, -$9.0 million in Q3 2025, and -$8.8 million in Q2 2025.